Trial Profile
A phase I study of CX-8998 for Essential tremor.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Suvecaltamide (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- 31 Jan 2017 New trial record